Roy Buchanan, an analyst from JMP Securities, reiterated the Buy rating on CureVac (CVAC – Research Report). The associated price target was lowered to $10.00.
Roy Buchanan has given his Buy rating due to a combination of factors including CureVac’s robust pipeline and financial stability. The company is advancing its cancer and infectious disease programs, with significant progress expected in the coming years. CureVac’s strong balance sheet, with €482 million at the end of 2024, provides an operational runway into 2028, supporting its ongoing and future clinical trials.
Additionally, CureVac’s legal victories, such as the recent positive ruling from the European Patent Office, bolster its position in the market. The upcoming clinical milestones, including the Phase 1 trial results for their cancer vaccine CVGBM and potential Phase 2 initiation, are anticipated to be major catalysts for the company’s growth. These strategic advancements and legal successes underpin Buchanan’s confidence in CureVac’s potential, justifying the Buy rating.